New cell therapy JY231 targets tough leukemia in early trial
NCT ID NCT06514768
First seen Jan 08, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This early study tests the safety and initial effectiveness of an investigational cell therapy called JY231 in people with B-cell acute lymphoblastic leukemia (B-ALL). About 20 participants will receive the treatment to see if it can help control the disease. The main goal is to check for side effects and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
920th HJointLogistics
RECRUITINGKunming, Yunnan, China
Conditions
Explore the condition pages connected to this study.